RUBICON RESEARCH LIMITED (RUBICON): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹1,771.7 latest close · +35.6% over the last 90 sessions

₹1,771.7 month-end · +170.1% over 12 months

₹1,771.7 month-end · +186.6% since Oct '25

52-week range ₹609.25 to ₹1899.00 · 1-year volatility 43.7%

Was the rally earned?

+170%share price, 1 yearEarnings and multiple

Both mattered.

Per-share earnings added 99 points and the multiple added 71 points (P/E 66.0x to 100.2x).
The share count rose 9%.

Net profit growth+113 ptsNet profit rose about 94%, which lifts the price.

P/E change+71 ptsThe P/E rose from 66.0x to 100.2x, which lifts the price.

Share count change-15 ptsShare count rose 9%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with BLISS GVS PHARMA

How rough has the ride been?

Maximum drawdown-23.4%not yet recovered

1-year volatility43.7%annualised

Volume spikes1last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-23.4% (2026-09 peak to 2026-10 low, not yet recovered)

-17.1% (2025-11 peak to 2025-12 low, recovered 2026-02)

Most recent volume spikes

2026-08-17: 13.1x the 50-day median, price +11.1% that day

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE87th▲ 4 pts vs a year ago
Op. margin72nd▲ 6 pts vs a year ago
Revenue growth89th
EPS growth86th
Debt/equity ↓50th▲ 41 pts vs a year ago
Cash cycle ↓8th▲ 5 pts vs a year ago
P/E ↓11th▼ 7 pts vs a year ago
12M momentum96th

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~54%annual earnings growth implied by the priceBelow delivered growth

At normalised P/E (five-year average earnings) of 373.0x, a holder earning 12%/yr needs earnings to grow about 54.4%/yr for 10 years, then trade at 15x.

Delivered143.0%/yrEPS, last 7 fiscal years · 3-yr avg to 3-yr avg

Gap−5.6 ptsimplied minus delivered

Rank636thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	56.5%	57.9%	59.3%
15x	53.1%	54.4%	55.8%
20x	48.7%	50.1%	51.4%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 54.4%/yr

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹1771.70
P/E: 100.2x
ROCE: 28.0%
Market Cap: ₹29338 cr
Revenue (TTM): ₹1936 cr
P/S: 15.2x
P/B: 22.8x
ROE: 22.7%
Operating Margin: 24.0%
Debt / Equity: 0.2x
Promoter Holding: 59.8%
12M Momentum: 170.1%

52-week range

₹609.25₹1899.00

90% of the way from its 52-week low to its high

Price risk

1Y volatility

43.7%

Beta vs sector

1-year daily

0.71

Balance sheet & cash

Interest cover

operating profit ÷ interest

10.3x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.82x

Share count, 1Y

+13.3%

Are profits backed by cash?

4 of 5checks within range1 beyond a threshold

Other income reliance4%Within range

Other income as a share of pre-tax profit (trailing twelve months): 3.8%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate23%Within range

Median quarterly effective tax rate over about 2.5 years: 23.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.82xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.82x (cash from operations ₹385 cr, net profit ₹472 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow1 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 1. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress8% of fixed assetsWithin range

Capital work-in-progress is 8% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

What happened next to similar setups

−9.4%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like RUBICON RESEARCH LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −26% to +14% vs the market, against 0% for all non-financial companies in the same months.
The gap against the base rate (−9.1%, 80% range −16.3% to +0.4%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median

−9.4%

All companies' median

−0.3%

Beat the market

42% vs 50%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ATGL Utilities	Jan 2020	80x	24%	+80%	−8%	+92%
GMMPFAUDLR Producer Manufacturing	Jun 2020	84x	31%	+203%	−9%	−30%
POLYMED Health Technology	Jul 2020	36x	25%	+123%	−5%	+61%
LAURUSLABS Health Technology	Oct 2020	67x	14%	+332%	−6%	+1%
SHAILY Process Industries	Sep 2025	86x	20%	+116%	−12%	+40%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
DOMS Producer Manufacturing	Mar 2025	88x	31%	+84%	−6%	−18%
AARTIDRUGS Health Technology	Sep 2020	51x	21%	+580%	−11%	−52%
KAYNES Electronic Technology	Jan 2024	173x	22%	+266%	−2%	+57%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, revenue growth and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to RUBICON RESEARCH LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

JYOTI CNC AUTOMATIONJYOTICNC

Producer Manufacturing

73%similar

market caprevenue

MANORAMA INDUSTRIESMANORAMA

Consumer Non-Durables

62%similar

volatilityoperating margin

ELECON ENGINEERING COLTDELECON

Producer Manufacturing

58%similar

promoter holdingoperating margin

NETWEB TECHNOLOGIES INDIANETWEB

Electronic Technology

55%similar

P/Emarket cap

SHAILY ENGINEERING PLASTICS LTSHAILY

Process Industries

55%similar

debt/equityROCE

CORONA REMEDIESCORONA

Health Technology

52%similar

debt/equityoperating margin

INVENTURUS KNOWLEDGE SOLUIKS

Health Technology

49%similar

market capdebt/equity

POLY MEDICUREPOLYMED

Health Technology

44%similar

operating marginrevenue

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

6 events since Feb '26

2026
OctDebtDebt / equity halved over 12 months to 0.24x.
OctSharesShare count is up 13.3% over 12 months.
AugPriceVolume reached 13.1x its 50-day median on 2026-08-17; price +11.1% that day.
JunDividendStarted paying a dividend (payout 10% of profit).
JunPriceVolume reached 45.5x its 50-day median on 2026-06-02; price +11.2% that day.
FebPriceVolume reached 9.3x its 50-day median on 2026-02-04; price +7.2% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history14 months · 2025-10 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	100.2x	₹1936 cr	22.7%	28.0%	0.2x
2026-10	91.0x	₹1936 cr	22.4%	28.0%	0.2x
2026-09	91.5x	₹1936 cr	22.4%	28.0%	0.2x
2026-08	118.4x	₹1754 cr	19.2%	28.0%	0.2x
2026-07	97.0x	₹1754 cr	19.2%	28.0%	0.2x
2026-06	91.3x	₹1754 cr	19.2%	28.0%	0.2x
2026-05	76.9x	₹1598 cr	38.1%	26.0%	0.8x
2026-04	74.2x	₹1598 cr	38.1%	26.0%	0.8x
2026-03	59.1x	₹1598 cr	38.1%	26.0%	0.8x
2026-02	70.0x	₹1435 cr	31.6%	26.0%	0.8x
2026-01	61.4x	₹1435 cr	31.6%	26.0%	0.8x
2025-12	61.1x	₹1435 cr	31.6%	26.0%	0.8x
2025-11	66.0x	₹1319 cr	27.9%	26.0%	0.8x
2025-10	62.3x	₹1319 cr	27.9%	26.0%	0.8x

Methodology and data notes